The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Rumoured Omeros IPO Might Signal Newly Opened Window

light at the end of the tunnel smallAn article in Xconomy Seattle today reports rumours that Omeros, a company that has been around since 1996 and has raised over $102 million in private money, may revive its 2008 IPO plans.

The company’s lead products — “proprietary low-dose combinations of existing drugs” — are more pharma than biotech, putting it in line with Cumberland’s recent IPO.  However, Omeros also has a pipeline of preclinical CNS and inflammation molecules, so if its IPO succeeds, it may indicate that the public markets are truly (despite some skepticism) opening again to biotechs.

Bookmark and Share

Advertisement

Leave a Reply

Fill in your details below or click an icon to log in:

Gravatar
WordPress.com Logo

Please log in to WordPress.com to post a comment to your blog.

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 80 other followers